logo
  

AbbVie Presents Positive Data On Upadacitinib In Active Psoriatic Arthritis And Axial Involvement

AbbVie (ABBV) said post-hoc analyses of the phase 3 SELECT-PsA 1 and SELECT-PsA 2 trials showed people with active psoriatic arthritis (PsA) demonstrated greater clinical responses related to axial involvement when treated with upadacitinib (RINVOQ) compared to placebo at week 24.

At week 24, upadacitinib showed numerically greater responses than adalimumab across all BASDAI and Ankylosing Spondylitis Disease Activity Score (ASDAS) endpoints in SELECT-PsA 1.

The proportion of patients achieving ASDAS clinically important improvement at week 24 was greater with upadacitinib (69.8%) versus adalimumab (54.1%, nominal P<0.05).
The company noted that findings from the post-hoc analysis are consistent with previous data based on investigator assessment alone.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Starbucks has dropped its vaccine or weekly test requirement against Covid-19 for U.S. employees in the wake of last week's U.S. Supreme Court ruling. The court, in a 6-3 vote, has blocked President Joe Biden's vaccine-or-test mandate for private companies with 100 or more employees. However, it allowed the vaccine mandate to stand for certain health care workers. Mylan Pharmaceuticals Inc., affiliated to healthcare company Viatris Inc., is recalling one batch of its non-interchangeable Semglee (insulin glargine injection), 100 units/ml (U-100), 3mL prefilled pens due to the potential for a missing label, the U.S. Food and Drug Administration said. Mushie & Co, LLC is recalling FRIGG Silicone Pacifiers citing choking risk, the U.S. Consumer Product Safety Commission said. The recall involves about 333,725 units of FRIGG silicone pacifiers that came in two designs: Classic and Daisy. According to the agency, the base of the silicone nipple has a fine slit that can cause the nipple to detach from the plastic shield, posing a choking hazard.
Follow RTT